What does Callan JMB do?
Callan JMB Inc. is a small, founder-led logistics and fulfillment company listed on the Nasdaq Capital Market under the ticker CJMB. Its operating focus is not ordinary parcel delivery. The company handles temperature-sensitive pharmaceuticals, biological materials, emergency-response supplies, and other products whose safety or potency can be damaged by time, temperature, humidity, handling, or incomplete chain-of-custody records. Its official investor profile describes an integrated service spanning fulfillment, storage, monitoring, and cold-chain logistics for healthcare organizations and emergency-management agencies.
Which activities sit inside the platform?
The platform combines reusable temperature-regulating packaging, warehousing, inventory handling, shipment preparation, emergency deployment, remote monitoring, and data archiving. Ship2Q manages inventory, while Sentry monitors temperature, humidity, and location. Regulated customers need evidence that products stayed within required conditions, not merely assurance that a package arrived.
| Capability | Customer need | Economic role |
|---|---|---|
| Cold-chain packaging | Maintain controlled or cryogenic temperatures for biologics and medical materials | Packaging access, preparation, leasing, and reuse support service revenue |
| Fulfillment and warehousing | Receive, store, pick, prepare, and deploy regulated products | Labor, facility, monitoring, and project-service fees |
| Emergency response | Rapid mobilization for governments, public-health agencies, and enterprises | Contracted preparedness and response assignments |
| Ship2Q and Sentry | Inventory visibility, environmental monitoring, and auditable shipment records | Embedded technology that supports retention and differentiated service pricing |
CJMB is a services business with technology and packaging embedded inside the service. It is not yet a scaled software platform or diversified global freight carrier. Its value proposition is operational reliability in regulated, high-consequence workflows.
How does Callan JMB make money?
Callan JMB earns revenue by solving logistics problems that require more control than standard shipping. Customers pay for coordinated service packages rather than clearly separated software subscriptions or product units. The FY2025 Form 10-K states that technical services and technology are bundled with emergency-response and perishable-packaging offerings and are not treated as separate revenue streams. This limits segment-level analysis: investors can observe total revenue and costs, but not the standalone economics of Sentry, packaging, warehousing, or emergency preparedness.
What drives gross profit?
Cost of revenue primarily includes outside service providers, monitoring, direct and indirect labor, warehouse rent, and related operating costs. Gross profit therefore depends on contract pricing, shipment or project volume, the amount of outsourced work, facility utilization, labor efficiency, and whether reusable packaging lowers lifecycle cost. The model can produce operating leverage when revenue rises faster than warehouse and support costs, but it can also show severe negative leverage when a major contract declines while corporate overhead remains.
| Revenue engine | Pricing logic | Main variable | Disclosure limitation |
|---|---|---|---|
| Government preparedness | Contracted scope, funding, storage, readiness, and deployment activity | Renewals, public-health budgets, emergency events | Customer names and contract-level profitability are generally not disaggregated |
| Life-sciences cold chain | Handling, packaging, warehousing, monitoring, and fulfillment fees | Shipment count, complexity, temperature range, geography | No separate revenue for packaging, software, or monitoring |
| Emergency response | Project and mobilization economics | Frequency, urgency, labor, equipment, subcontracting | Revenue can be irregular and seasonal |
| New regulated programs | Potential oversight, deployment, or commercialization fees | Regulatory milestones and customer execution | Announced opportunity is not the same as recognized revenue |
What does the latest quarter show?
The latest official financial package is the Form 10-Q for the quarter ended March 31, 2026. It shows a business whose revenue base contracted while public-company, financing, and operating costs remained high. Revenue fell because of the non-renewal of a government contract and lower non-government customer revenue.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $1.106M | $1.449M | Down 23.7%; contract loss and weaker non-government demand |
| Gross profit | $0.427M | $0.616M | Down 30.6%; gross profit fell faster than revenue |
| Gross margin | 38.6% | 42.5% | A 3.9-point decline, based on reported revenue and gross profit |
| SG&A expense | $2.128M | $1.854M | Up 14.8% despite lower revenue |
| Net loss per share | $(0.59) | $(0.32) | Loss widened as operating and ELOC-related costs increased |
| Operating cash use | $(1.680)M | $(1.562)M | Cash burn remained large relative to quarterly revenue |
Why is the margin signal important?
Which turning points created today’s Callan JMB?
CJMB’s history is best understood as a transition from an operating cold-chain business into a public micro-cap seeking to broaden its addressable market. The turning points below matter because each changed either the service platform, the capital structure, or the regulatory burden.
-
2006Coldchain Technology Services was formed in Texas. The long operating history underpins the company’s emergency-response and temperature-control know-how.
-
2023The company entered a professional-services relationship with the City of Chicago’s public-health department, illustrating the importance of government preparedness contracts.
-
January 2024The business reorganized under Nevada holding company Callan JMB Inc., creating the structure used for public ownership.
-
February 2025CJMB completed its IPO, issuing 1.28 million shares at $4.00 and later additional over-allotment shares. The company reported approximately $5.776 million of gross proceeds and about $4.7 million of net proceeds.
-
July 2025A $25 million equity line of credit expanded financing access but introduced dilution and derivative-accounting costs.
-
January 2026The company announced an Attune Biotech teaming agreement covering manufacturing oversight, deployment, and commercialization. CJMB cited a potential $50 million to $75 million total-revenue opportunity, but this is prospective rather than recognized revenue.
-
April–June 2026Nasdaq issued separate notices concerning stockholders’ equity and the $1.00 minimum bid price, making listing compliance part of the near-term strategic agenda.
What changed after the IPO?
The IPO gave CJMB cash and a public currency, but it also raised legal, audit, investor-relations, insurance, and compensation expenses. FY2025 SG&A rose 77% to $8.60 million while revenue declined to $5.72 million. The IPO closing announcement is therefore both a financing milestone and the beginning of a cost transition that the operating business has not yet absorbed.
What gives Callan JMB a competitive advantage?
CJMB’s most credible advantage is integration across packaging, regulated handling, warehousing, emergency deployment, monitoring, and documentation. A customer moving vaccines, cell therapies, diagnostic materials, reproductive tissue, infectious samples, or other sensitive products may prefer one accountable provider rather than multiple vendors whose handoffs create gaps. The company also cites reusable packaging, rapid response, experienced personnel, and compliance licenses as differentiators.
Is the moat durable?
The moat is useful but not yet proven at scale. The company competes with local and national service firms, packaging manufacturers, cryogenic equipment providers, and specialty couriers with much larger resources. CJMB says no single competitor matches its full suite, but breadth alone does not guarantee pricing power. A larger provider could bundle comparable services, price aggressively, or invest more heavily in technology and distribution.
| Competitive factor | CJMB position | Limitation |
|---|---|---|
| Breadth of service | Integrated packaging, fulfillment, monitoring, storage, and response | Capabilities are not reported by segment, so their standalone economics are unclear |
| Regulatory readiness | State licenses and disclosed compliance with pharmaceutical distribution standards | Compliance is costly, and failures could cause recalls, fines, or loss of licenses |
| Carrier alliances | Agreements with FedEx, DHL, and UPS can support end-to-end reach | The agreements contain no minimum usage commitment |
| Scale | A focused organization can respond quickly and customize projects | Twenty employees and limited capital constrain sales coverage and fixed-cost absorption |
How strong are liquidity, cash flow, and capital allocation?
Financial strength is currently the central constraint. At March 31, 2026, CJMB held $1.416 million of cash and $3.034 million of current assets against $1.515 million of current liabilities. The resulting current ratio was about 2.0, but that snapshot must be read alongside $1.680 million of cash used in operations during the quarter. A company can have positive working-capital coverage and still face a short runway when operating burn is high.
| Financial item | Latest amount | Period | Analytical meaning |
|---|---|---|---|
| Cash and equivalents | $1.416M | March 31, 2026 | Liquidity buffer declined by $0.715M during Q1 2026 |
| Stockholders’ equity | $1.600M | March 31, 2026 | Below Nasdaq’s $2.5M continued-listing threshold cited in the April notice |
| Total liabilities | $4.111M | March 31, 2026 | About 72.0% of total assets; much relates to leases and the derivative liability |
| Operating cash flow | $(1.680)M | Q1 2026 | Negative cash conversion despite positive gross profit |
| Capital expenditure | $0.035M | Q1 2026 | Small relative to operating burn; related to office build-out and equipment |
| Shares outstanding | 5.646M | March 31, 2026 | Up 16.2% from 4.859M at December 31, 2025 |
How did FY2025 cash move?
What is management using to finance the gap?
The capital plan has relied on equity. The 2025 IPO, a $25 million ELOC, and a May 2026 at-the-market program provide access to funding, but each can increase the share count. The May 2026 registration statement contemplated up to $5 million of ATM common-stock sales, subject to market and regulatory limitations. CJMB has never paid a dividend and intends to retain any future earnings for growth.
Who owns Callan JMB, and why does control matter?
Callan JMB has one class of common stock with one vote per share, but ownership has historically been concentrated in founder and executive hands. The most detailed official beneficial-ownership table available in the company’s September 2025 prospectus used an August 22, 2025 measurement date. It showed Wayne Williams with 2,338,125 beneficially owned shares, or 52.17%, David Croyle with 822,375 shares, or 18.35%, and directors and executive officers as a group with 3,310,500 shares, or 73.87%.
| Holder or group | Beneficial ownership | Percent | Source period | Why it matters |
|---|---|---|---|---|
| Wayne Williams | 2,338,125 shares | 52.17% | August 22, 2025 | Founder, CEO, president, and then majority holder; strong influence over directors and strategic actions |
| David Croyle, M.D. | 822,375 shares | 18.35% | August 22, 2025 | Significant insider alignment and influence |
| Executives and directors as a group | 3,310,500 shares | 73.87% | August 22, 2025 | Public holders had limited ability to change control without insider support |
| Common stock structure | One vote per share | No dual class | Prospectus terms | Control comes from concentrated ownership, not super-voting stock |
How should investors interpret the dated percentages?
The exact ownership percentages have likely changed as shares were issued under the ELOC and equity-compensation plans. Shares outstanding rose to 5.646 million by March 31, 2026. The FY2025 filing still classified CJMB as a Nasdaq “controlled company,” meaning a controlling group could qualify for exemptions from some independent-board and committee requirements, although the company said it did not then intend to use those exemptions.
Governance also matters because CJMB uses related-party facilities. The FY2025 filing disclosed $110,700 of rent expense to Outlaw Run Ranch and $186,366 associated with Warehouse Asset Management. Related-party transactions are not necessarily unfavorable, but they require disciplined board oversight, transparent pricing, and careful comparison with market alternatives.
Where could growth come from?
Management is trying to reuse the same cold-chain, compliance, and emergency-response competencies across new customer groups. The best opportunities add revenue to existing facilities and systems without recreating the cost base.
How important is the Attune opportunity?
In January 2026, CJMB announced a strategic teaming agreement with Attune Biotech covering manufacturing oversight, federal deployment, and commercialization of a therapeutic pipeline. The company described an estimated $50 million to $75 million total-revenue opportunity. That figure is potentially transformative relative to FY2025 revenue of $5.72 million, but it should not be inserted into a base-case forecast as contracted revenue. Clinical, regulatory, manufacturing, funding, and commercialization milestones can delay or reduce realization. The official Attune announcement is best treated as an opportunity pipeline disclosure.
Can regulatory approvals become a commercial asset?
Yes, when they shorten customer onboarding or permit CJMB to receive, store, and deploy products competitors cannot readily handle. The company’s June 2026 Oregon VFC authorization is an example. The commercial value, however, will be visible only when authorizations convert into funded programs, recurring volumes, and margin contribution.
Why do concentration and Nasdaq compliance dominate the risk case?
CJMB’s risks are unusually concentrated. This is not a large logistics network where thousands of customers diversify demand. In Q1 2026, one customer generated 67% of revenue, the second generated 13%, and the third generated 11%. Together, the top three represented 91% of quarterly revenue. A single renewal or non-renewal can therefore change reported growth, facility utilization, gross margin, and liquidity.
| Risk | Current evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Customer concentration | Top three customers were 91% of Q1 2026 revenue | Revenue, gross profit, receivables, cash burn | Renewals, funding levels, and new-customer contribution |
| Going concern | FY2025 and Q1 2026 filings cite substantial doubt | Liquidity, financing cost, dilution | Cash runway and operating-cash-use trend |
| Nasdaq equity compliance | $1.600M equity at March 31, 2026 versus $2.5M rule threshold | Listing status and financing access | Compliance plan and equity restoration |
| Minimum bid price | June 29, 2026 notice; initial deadline December 28, 2026 | Potential reverse split, trading liquidity | Ten or more consecutive business days at or above $1.00 |
| Regulatory and product liability | Biologics, hazardous materials, and temperature failures can create claims | Insurance, legal cost, customer retention | Compliance findings, recalls, claims, and insurance limits |
| Dilution | Shares rose 16.2% in Q1 2026; ELOC and ATM remain financing tools | Per-share value and insider control | Share count, issuance price, and cash raised |
What do the listing notices mean?
The April 2026 stockholders’ equity notice said the company was below Nasdaq’s $2.5 million requirement. The June 29, 2026 minimum-bid-price notice provided an initial compliance period through December 28, 2026. Neither notice immediately delisted the stock, but both increase the importance of equity issuance, operating improvement, or a reverse split.
What is the key takeaway for valuation and monitoring?
Callan JMB operates where logistics failure has unusually high consequences. Temperature control, chain-of-custody evidence, emergency readiness, and integrated fulfillment can create customer value. Yet the platform is subscale: revenue is declining, gross profit does not cover SG&A, cash burn is substantial, and equity financing is dilutive.
Which variables belong in a DCF?
A sensible model should separate the existing business from unproven opportunities. The base case should begin with FY2025 revenue of $5.72 million, Q1 2026 revenue of $1.11 million, a Q1 gross margin of 38.6%, and the current cost structure. Upside scenarios may incorporate contract renewals, new public-health programs, higher facility utilization, and Attune-related milestones only as evidence emerges. The discount rate and terminal assumptions should reflect going-concern risk, customer concentration, dilution, listing compliance, and the small public float.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.